Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric PatientsArticle Published on 2021-08-192022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] activity Adults affected Analysis anti-malarial drug antiviral activity antiviral drug antiviral drugs approach can be used children clinical trial Concentration COVID-19 criteria defined dose dose rationale drug estimate evaluate extrapolation implication in vitro data include Intervention Lungs Medicine MIDD model-informed drug development MOST paediatrics parameter patient population pharmacokinetic data pharmacological Probability rationale regimen Remdesivir repurposing required robust safety margin SARS-CoV-2 SARS-COV-2 infection Toxicity Treatment Trial viral clearance [DOI] 10.3390/pharmaceutics13081299 PMC 바로가기 [Article Type] Article
Model-Informed Drug Development for Malaria Therapeutics말라리아 치료제를 위한 모델 기반 약물 개발Original Article Published on 2017-10-062024-08-26 Journal: Annual Review of Pharmacology and Toxicology [Category] 말라리아, [키워드] Controlled human malaria infection disease-drug model malaria model-informed drug development Pharmacodynamics pharmacokinetics [DOI] 10.1146/annurev-pharmtox-010715-103429 PMC 바로가기 [Article Type] Original Article